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Take-home message: CMV-seropositive
critically ill patients with ARDS who
remain mechanically ventilated for more
than 4 days have a 27 % cumulative risk of
developing CMV reactivation while in the
ICU. Despite extensive statistical correction
to account for time-varying aspects of
exposure, competing risks, and the presence
of confounding by differences in the
evolution of disease severity prior to
viremia onset, CMV reactivation remains
independently associated with increased
case fatality. The absolute mortality due to
these reactivations is estimated at 4.4 %
(95 % CI 1.1–7.9) by day 30.
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occurs frequently in patients with the
acute respiratory distress syndrome
(ARDS) and has been associated with
increased mortality. However, it
remains unknown whether this
association represents an independent
risk for poor outcome. We aimed to
estimate the attributable effect of
CMV reactivation on mortality in
immunocompetent ARDS patients.
Methods: We prospectively studied
immunocompetent ARDS patients
who tested seropositive for CMV and
remained mechanically ventilated
beyond day 4 in two tertiary intensive
care units in the Netherlands from
2011 to 2013. CMV loads were
determined in plasma weekly. Com-
peting risks Cox regression was used
with CMV reactivation status as a
time-dependent exposure variable.
Subsequently, in sensitivity analyses
we adjusted for the evolution of dis-
ease severity until onset of
reactivation using marginal structural
modeling. Results: Of 399 ARDS
patients, 271 (68 %) were CMV
seropositive and reactivation occurred
in 74 (27 %) of them. After adjust-
ment for confounding and competing
risks, CMV reactivation was associ-
ated with overall increased ICU
mortality (adjusted subdistribution
hazard ratio (SHR) 2.74, 95 % CI
1.51–4.97), which resulted from the
joint action of trends toward an
increased mortality rate (direct effect;
cause specific hazard ratio (HR) 1.58,
95 % CI 0.86–2.90) and a reduced
successful weaning rate (indirect
effect; cause specific HR 0.83, 95 %
CI 0.58–1.18). These associations
remained in sensitivity analyses. The
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population-attributable fraction of
ICU mortality was 23 % (95 % CI
6–41) by day 30 (risk difference 4.4,
95 % CI 1.1–7.9). Conclu-
sion: CMV reactivation is
independently associated with
increased case fatality in immuno-
competent ARDS patients who are
CMV seropositive.
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Introduction
Although the burden of cytomegalovirus (CMV) disease
has been well established in immunocompromised
patients [1], CMV viremia has also been described in
intensive care unit (ICU) patients without known prior
immune deficiency. This almost exclusively results from
systemic viral reactivation, and incidence rates of up to
40 % have been reported in critically ill CMV seroposi-
tive subjects [2–9]. Furthermore, CMV reactivation in
critically ill patients has been associated with a prolonged
duration of mechanical ventilation [2, 4, 9–13], an
increased length of stay in the ICU [3, 5, 9, 10, 13], and
excess mortality [2, 4, 7–9]. Nevertheless, it remains
uncertain whether these findings imply that CMV reacti-
vation is a truly independent risk factor with respect to
these observed poor clinical outcomes because most
studies that have assessed these associations did not
adequately account for all possible sources of bias. As a
consequence, CMV viremia might merely be a marker of
illness severity, contributing only little to the overall
burden of disease.
To achieve an accurate estimation of the true effect of
CMV reactivation on clinical outcome, it is crucial in
observational studies to adjust for the time-dependent
occurrence of CMV reactivation and the evolution of
disease severity prior to its onset. Moreover, the presence
of competing events should be taken into account when
follow-up time is censored [14]. For instance, when ICU
mortality is the outcome, then ICU discharge is a com-
peting risk that prohibits the event of interest from
occurring first.
Patients with acute respiratory distress syndrome
(ARDS) often have a long and complicated disease course
in the ICU, which portends a particular risk for viral
reactivations [15, 16]. Despite the uncertainties regarding
the clinical relevance of CMV disease in immunocom-
petent critically ill patients, it is etiologically plausible
that virus reactivation adds to the pulmonary pathology in
patients with ARDS. In experimental murine studies,
CMV reactivation caused exacerbated and prolonged
cytokine and chemokine expression in lung tissues, which
eventually led to increased pulmonary fibrosis compared
to controls [17]. In a clinical study of open lung biopsies
in ARDS patients with prolonged respiratory failure or in
whom microbiological cultures remained negative, CMV
pneumonia was found in 30 % of cases [18]. Both
findings suggest that CMV-related pulmonary pathology
may be causally linked to the clinical disease course
following ARDS onset, especially in the most severely ill
patients who require prolonged mechanical ventilation. If
CMV reactivation does contribute to poor clinical out-
come in these patients, either prophylaxis or pre-emptive
therapy with (val)ganciclovir may be considered.
The aim of this study was to estimate the proportion of
deaths that can be attributed to systemic reactivation of
CMV in ARDS patients who are latent carriers of the
virus. Some results of this study have been previously
reported in the form of an abstract [19].
Methods
Patients and measurements
The present study was conducted within the framework
of the Molecular Diagnosis and Risk Stratification of
Sepsis (MARS) cohort (clinicaltrials.gov identifier:
NCT01905033) for which the institutional review board
approved an opt-out method of informed consent (proto-
col number 10-056C) [20]. We prospectively included
consecutive adults who presented with ARDS to the
mixed ICUs of two tertiary care hospitals in the Nether-
lands between January 2011 and December 2013 and
required mechanical ventilation beyond day 4 of ICU
admission. Since data collection for our study started
before publication of the Berlin definition in 2012, ARDS
was defined according to the American-European Con-
sensus Conference criteria [21]: that is, the diagnosis
required an acute onset of symptoms, the presence of
bilateral infiltrates on chest radiography, a pulmonary
artery occlusion pressure less than 18 mmHg and/or the
absence of left ventricular dysfunction, and PaO2/FiO2
ratio (P/F) less than 300. We excluded patients who had
received (val)ganciclovir, (val)acyclovir, cidofovir, or
foscarnet in the week before ICU admission and those
with known immunodeficiency [16]. Immunodeficiency
was defined as a history of solid organ or stem cell
transplantation, infection with the human immunodefi-
ciency virus, hematological malignancy, use of
immunosuppressive medication (more than 0.1 mg pred-
nisone per kilo for more than 3 months, more than 75 mg
prednisone per day for more than 1 week, or equivalent),
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chemotherapy/radiotherapy in the year before ICU
admission, and any known humoral or cellular immune
deficiency.
Leftover plasma, which was harvested from blood
samples obtained daily as part of routine patient care, was
stored at -80 C within 4 h after blood draw. CMV
serostatus was determined by an enzyme immunoassay
(Enzygnost CMV/IgG, Siemens Healthcare Diagnostic
Products, Marburg, Germany). Subsequently, in seroposi-
tive patients only, viral loads in plasma were determined by
real-time Taqman CMV-DNA polymerase chain reaction
[22]. CMV loads were determined on a weekly basis for a
maximum of 30 days following study inclusion (i.e., day 5
of ICU admission). For intermediary days, on which quan-
titative PCR was not performed, we estimated viral loads by
log-linear imputation. CMV reactivation was defined as a
viral load of at least 100 international units per milliliter
(IU/mL), as calibrated according to the CMV World Health
Organization (WHO) Standard. Screening for CMV was not
part of routine clinical practice in either participating hos-
pital. Neither serology results nor viral loads measured as
part of our study were made available to the treating
physicians, and none of the included patients therefore
received antiviral treatment directed against CMV.
Mortality was the outcome of primary interest in this
study and was defined as death on mechanical ventilation
before day 35 (i.e., day 30 following study inclusion).
Successful weaning, which is a competing event of the
primary outcome, was defined as complete liberation
from mechanical ventilatory support on two or more
consecutive days before day 35. We considered distal end
points more likely to be amenable by pre-existing
comorbidities, as well as specific end-of-life practices,
bed availability, and other local factors. Nonetheless, in a
subsequent sensitivity analysis, we used discharge and
death in ICU as alternative end points.
Data analysis
For our primary analyses we used Cox proportional haz-
ards modeling, in which mortality and successful weaning
were considered as competing events and CMV reacti-
vation status was fitted as a time-dependent variable.
Possible confounders that were screened included
all patient characteristics and therapeutic interventions
listed in Table 1, and some markers of disease severity:
Acute Physiology and Chronic Health Evaluation
Table 1 Characteristics of ARDS patients by CMV reactivation status
Reactivation (n = 74) Non-reactivation (n = 197) p value
Patient characteristics
Age (years) 64 (56–74) 64 (54–72) 0.50
Male gender 44 (59) 120 (61) 0.83
Non-European descent 13 (18) 27 (14) 0.42
Prior ICU admission during hospital stay 16 (22) 24 (12) 0.05
Surgical reason for admission 22 (30) 73 (37) 0.26
COPD 13 (18) 30 (15) 0.64
Congestive heart failure 2 (3) 9 (5) 0.49
Diabetes mellitus 14 (19) 26 (13) 0.24
Cancer 9 (12) 28 (14) 0.66
Renal insufficiency 12 (16) 11 (6) \0.01
Markers of disease severity
APACHE IV score 91 (71–113) 76 (62–99) \0.01
Septic shock 42 (57) 81 (41) 0.02
Plasma lactate 3.6 (1.9–6.5) 3.5 (1.9–5.8) 0.47
C-reactive protein 244 (129–310) 241 (151–309) 0.99
C3 quadrant consolidation 49 (66) 121 (61) 0.47
Tidal volume (mL/kg body weight) 6.5 (5.5–7.6) 6.5 (5.6–7.8) 0.72
PEEP setting (cmH2O) 12 (10–15) 10 (8–15) 0.16
P/F 107 (77–150) 106 (82–149) 0.41
Pulmonary compliance (mL/cmH2O) 35 (24–47) 39 (27–49) 0.15
Therapeutic interventions
High dose corticosteroid therapy 48 (65) 101 (51) 0.05
Transfusion of blood products 15 (20) 18 (9) 0.18
Markers of disease severity represent the worst values observed
during the first 4 days in ICU, except for tidal volume, which
represents the mean value. Therapeutic interventions relate to the
first 4 days in ICU only. High dose corticosteroid was defined as a
daily dose of C250 mg hydrocortisone or equivalent
Data are presented as medians (interquartile range) or absolute
numbers (%). p values were calculated by nonparametric tests and
Chi square tests, respectively
APACHE Acute Physiology and Chronic Health Evaluation, ARDS
acute respiratory distress syndrome, COPD chronic obstructive
pulmonary disease, ICU intensive care unit, PEEP positive end
expiratory pressure, P/F partial pressure of oxygen in arterial blood
to fraction of inspired oxygen ratio
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(APACHE) IV score, presence of septic shock, partial
pressure of oxygen in arterial blood to fraction of inspired
oxygen ratio, and positive end expiratory pressure (PEEP)
setting. To account for possible confounding, we included
baseline covariables that showed differences between the
reactivated and non-reactivated groups at a p value of less
than 0.30, and changed the crude effect estimates for
either mortality or weaning by more than 10 %. We
included only the strongest (possible) confounders by
using these two criteria combined in order to avoid sta-
tistical overfitting (i.e., incorporating too many variables
given the limited number of events).
The two possible outcomes are interrelated as
increased mortality may negatively impact the duration of
mechanical ventilation. A competing risks analysis
accommodates for this by providing two measures of
association. First, the cause-specific hazard ratio (CSHR)
estimates the direct effects of CMV reactivation on each
outcome of interest (i.e., mortality on the ventilator and
successful weaning). Second, the subdistribution hazard
ratio (SHR) estimates the risk of dying from reactivation
at a given time-point, while accounting for the competing
risk of successful weaning. To obtain direct estimates of
cumulative risks in terms of the SHR we used the Fine
and Gray model [23]. Finally, to estimate the population-
attributable fraction of mortality due to CMV reactiva-
tion, we used a multi-state model (Fig. S1), which
accounts for the time of reactivation [24]. Confidence
intervals were calculated by bootstrap resampling [25,
26].
Despite these efforts to accurately assess the effect
of CMV reactivation on clinical outcomes, residual
confounding may still remain, because markers of ill-
ness at baseline (which we included in all multivariable
analyses) may no longer be representative of the disease
state at the time of reactivation onset. Thus, we per-
formed a sensitivity analysis using marginal structural
modeling to adjust for the evolution of disease severity
prior to the onset of CMV reactivation (see also Sup-
plementary Material) [27, 28]. Such analysis first
involves estimation of the daily probabilities of CMV
reactivation using a multivariable logistic regression
model that includes markers of disease severity on a
daily basis. These probabilities are used to calculate an
inversed probability weight that is then included as a
summary measure of all relevant covariables in the final
Cox regression model. However, because marginal
structural modeling requires many assumptions that are
difficult to be checked, we considered this a sensitivity
analysis only.
Data were analyzed with SAS 9.2 (Cary, NC, USA)
and R 2.15.1 software (R Foundation for Statistical
Computing, Vienna, Austria; packages ‘‘etm’’, ‘‘mstate’’,
‘‘ipw’’).
Results
We enrolled 544 patients with ARDS who required
mechanical ventilation for more than 4 days (Fig. S2). Of
these 143 were excluded because of known prior
immunocompromise or antiviral treatment and two were
excluded because of missing samples. Subsequently, 271
(68 %) patients tested seropositive for CMV and were
thus included in the study. ARDS was of primary pul-
monary origin in 158 (58 %) of these cases, whereas the
remainder was of secondary etiology (e.g., associated
with non-pulmonary sepsis, major surgery, or blood
transfusion).
CMV reactivation
CMV reactivation occurred in 74 (27 %) of the included
patients (Table 1). These patients more frequently had—
at the time of ICU admission—concurrent septic shock,
higher APACHE IV scores, and renal insufficiency
compared to patients who never had CMV reactivation. In
addition, a larger proportion of these patients were
receiving high dose corticosteroid therapy during the first
days in ICU. The median time from ICU admission to
onset of reactivation was 8.5 days (interquartile range
(IQR) 4–11). Within the subgroup of patients acquiring
CMV reactivation the proportion of individuals having
relatively high viral loads (at least 1000 IU/mL) increased
over time (Fig. 1). In a patient population that is selected
by an ICU stay of at least 5 weeks, the proportion with
CMV viremia is as high as 14 of 23 patients (61 %).
Clinical outcomes
On day 30 after study inclusion (this was 35 days fol-
lowing ICU admission) 52 (19 %) patients had died, 209

















Fig. 1 Viral load in CMV seropositive ARDS patients over time.
The quantitative PCR results were calibrated according to the CMV
WHO standard; viral loads greater than or equal to 1000 IU/mL
were denoted ‘high reactivation’. Viral loads of 100–999 IU/mL
were denoted ‘low reactivation’, and undetectable loads or viral
loads below 100 IU/mL were denoted ‘no reactivation’
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(77 %) were successfully weaned, and 10 (4 %) remained
still on mechanical ventilation (Table 2). In crude anal-
yses, patients with CMV reactivation had both a longer
duration of mechanical ventilation (15 (IQR 10–26) vs. 8
(IQR 6–12) days; p\ 0.01) and higher mortality (23 of
74 (31 %) vs. 29 of 197 (15 %) patients; p\ 0.01)
compared to subjects without reactivation.
Table 3 shows the results of the various Cox survival
regression analyses. Baseline variables associated with
reactivation status (at p\ 0.30) which changed the crude
effect estimate by more than 10 % included the APA-
CHE IV score, use of high dose corticosteroid therapy,
and PEEP setting.
In the primary multivariable adjusted analysis, CMV
reactivation was no longer statistically associated with
either increased mortality or a reduced rate of successful
weaning. However, simultaneous effects on both the
daily rates of death and weaning did reveal a significant
association with overall mortality when competing risks
were accounted for (SHR 2.74, 95 % CI 1.51–4.79). As
a post hoc sensitivity analysis, we then used marginal
structural modeling to assess potential residual
confounding by differences in the evolution of disease
severity prior to CMV reactivation between both groups,
but found very similar results (Table 3). Changing the
definitions of our primary end points to include all
deaths in the ICU (irrespective of mechanical ventilation
status) and discharge (rather than successful weaning)
also did not change these findings (Table S1). Further-
more, the independent association with mortality
remained among subgroups of patients receiving and not
receiving high dose corticosteroid therapy; SHR 2.60
(95 % CI 1.29–5.25) and 3.61 (95 % CI 1.24–10.48),
respectively (Table S2). Corticosteroids were mostly
used for the treatment of concurrent septic shock (121 of
149 cases).
Figure 2 shows the predicted mortality in a hypo-
thetical population of ARDS patients in which all CMV
reactivation is prevented, compared to true (observed)
mortality in the study population. The population-at-
tributable fraction of ICU mortality due to CMV
reactivation was estimated at 23 % (95 % CI 6–41 %) by
day 30, which translates into an absolute mortality dif-
ference of 4.4 % (95 % CI 1.1–7.9).
Table 2 Crude clinical outcomes of ARDS patients by CMV reactivation status
Reactivation Non-reactivation p value
Death on ventilator before day 30a 23/74 (31) 29/197 (15) \0.01
Death in ICUb 26/76 (34) 32/195 (16) \0.01
Death by day 90b 35/76 (46) 55/195 (28) \0.01
Duration of mechanical ventilation (days) 15 (10–26) 8 (6–12) \0.01
Length of stay in ICU (days) 16 (11–28) 9 (7–14) \0.01
a Primary study end point
b CMV reactivation occurred in two additional patients after suc-
cessful weaning in the ICU; therefore, 76 instead of 74 patients
were considered exposed for analyses with more distal end points
(death in ICU, death by day 90). Data show absolute numbers (%)
or medians (interquartile range)







Crude model with adjustment for
time-varying onset of CMV reactivation
0.81 (0.58–1.13) 1.75 (1.01–3.01) 3.39 (1.96–5.87)
Multivariable model with adjustment for
time-varying onset of CMV reactivation
baseline imbalancesa
0.83 (0.58–1.18) 1.58 (0.86–2.90) 2.74 (1.51–4.97)
Multivariable model with adjustment for
time-varying onset of CMV reactivation
baseline imbalancesa
evolution of disease prior to onset of CMV reactivationb
0.93 (0.66–1.31) 1.49 (0.78–2.85) 2.48 (1.32–4.66)
Data are presented as hazard ratios with 95 % CI. The cause-
specific hazard ratio (CSHR) estimates the direct effect of CMV
reactivation on clinical outcome (i.e., successful weaning or death
on mechanical ventilation). The subdistribution hazard ratio (SHR)
is a summary measure of both separate cause-specific hazards and
estimates the overall risk of dying from CMV reactivation while
taking into account the competing event of successful weaning
a APACHE IV score, use of high dose corticosteroid therapy, and
PEEP setting
b Time-dependent covariables included the risk, injury, failure, loss
and end-stage kidney disease (RIFLE) score, Sequential Organ
Failure Assessment (SOFA) score, presence of septic shock, and
use of high dose corticosteroid therapy, which were all measured on
a daily basis until 24 h prior to reactivation onset
337
In order to explore possible causal pathways for the
observed association between CMV reactivation and
death, we performed a post hoc descriptive analysis of the
trajectories of organ dysfunction, pulmonary and inflam-
matory markers over time following reactivation. In short,
we compared the 74 patients having CMV reactivation
with 74 non-exposed patients who were matched on
baseline characteristics and their length of stay in ICU at
the onset of reactivation (Table S3). In summary, the total
burden of organ dysfunction was slightly higher in
patients at the start of CMV reactivation compared to
matched non-exposed control subjects, although individ-
ual markers of pulmonary dysfunction and inflammation
were similar. More importantly, there was a clear trend
towards resolution of organ dysfunction over time in non-
exposed subjects that was less pronounced in patients
having CMV reactivation. However, it should be
emphasized that these findings should be interpreted very
carefully because of the presence of informative censor-
ing (i.e., patients who die or get discharged do not further
contribute to average scores on the group level).
Discussion
CMV reactivation in ARDS patients increased the overall
risk of death on the ventilator through the combined effect
of subtle alterations in both the daily rates of death and
successful weaning. After accounting for multiple sources
of confounding, the absolute mortality that can be
attributed to CMV reactivation was estimated to be 4.4 %
by day 30 following study inclusion.
Previous findings of excess mortality have triggered
debate whether antiviral prophylaxis should be used [29,
30]. However, a greater understanding of pathophysiology
and clinical risk factors is necessary to select the optimal
target population for such strategies. In our study, reac-
tivation rates were 27 % in ARDS patients overall and
34 % among those with concurrent septic shock. The
latter finding might be explained by the increased severity
and duration of immune suppression that may be observed
in patients with septic shock, including a pronounced
depletion of T cells [31, 32]. Indeed, a recent study
investigating the potential use of antiviral prophylaxis
based on the screening of ARDS patients for CMV
seroprevalence found that such a strategy is unlikely to be
beneficial overall, but suggested a possible benefit in a
post hoc subgroup of patients with septic shock [16]. As
the proportion of patients with CMV reactivation
increased in time, altering the minimal length of stay in
the ICU as a criterion may also improve the selection of a
high-risk target population. Until then, a pre-emptive
treatment strategy (by which patients would be screened
for CMV and treated only if reactivation occurs) seems
more attractive because the number of patients exposed to
the toxicity of (val)ganciclovir would be reduced by
73 %. However, the effects of pre-emptive compared to
prophylactic treatment on relevant patient outcomes are
most likely lower, as treatment is initiated only after
reactivation has already begun. Intervention trials com-
paring prophylaxis, pre-emptive treatment, and wait-and-
see strategies are necessary before any evidence-based
recommendations regarding the clinical management of
CMV reactivation in critically ill patients with ARDS can
be made.
Our study has several strengths. First, observations
were nested within a large prospective data collection
initiative that included consecutive patients, thereby
minimizing selection bias [20]. All ARDS events were
diagnosed by dedicated trained observers, which mini-
mizes information bias. Moreover, we used a highly
sensitive method of quantitative real-time PCR for CMV
detection. Most importantly, we used advanced method-
ologies to account for both competing risks and time-
dependent information in an attempt to produce unbiased
estimates of the independent association between CMV
reactivation and clinical outcome.
This methodological approach was mainly necessary
because of two reasons. First, Cox regression analysis
requires that censoring of survival time must be non-in-
formative, but in our study this was clearly not the case
since ARDS patients who are weaned and discharged
from the ICU alive are in a better health state than those
who remain on the ventilator beyond that time point [33,
34]. Furthermore, when ICU mortality is the event of
interest, then discharge must be regarded as a competing
event as it precludes this outcome from being observed
[14]. The use of the subdistribution hazard model pro-
vides a general solution to this informative censoring.
Second, the median time to CMV reactivation in our
cohort was 8.5 (IQR 4–11) days. If ignored, such delays















Fig. 2 Observed versus predicted ICU mortality in CMV seropos-
itive ARDS patients. The blue line represents the observed ICU
mortality in the study cohort of 271 CMV seropositive patients; the
green line represents the predicted ICU mortality if all cases of
CMV reactivation in the cohort are prevented. The population-
attributable fraction of ICU mortality was 23 % by day 30
(absolute risk difference 4.4 %)
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may cause distortion (termed immortal time bias) as non-
exposed time observed before the onset of reactivation
will be wrongfully attributed to the exposed time at risk,
resulting in underestimation of effects associated with
CMV reactivation [35, 36]. Time-dependent fitting of
CMV reactivation status in our regression models
resolved this issue.
Our study also has several limitations. First, even the
use of advanced methodology cannot rule out the possi-
bility of unmeasured confounding in an observational
study. Therefore, it remains somewhat uncertain whether
the excess mortality that we observed can be fully
attributed to CMV reactivation, or whether other
unknown factors—including other viral reactivations [8,
37]—may also be involved. Second, the principle of
multivariable analysis to adjust for confounders is to
statistically ‘force’ exposed and non-exposed patients to
be similar in all aspects of disease aside from their
reactivation status. However, in a dynamic ICU setting,
during which critically ill patients continuously deterio-
rate and improve over time, it is very difficult to verify
whether such adjustment was successful. We performed
marginal structural modeling as a sensitivity analysis to
assess the possible impact of variations in the evolution of
disease severity between patients on our effect estimates,
yet found very similar results as in our primary analysis.
Third, we measured systemic CMV reactivation in plasma
but did not collect information about concurrent viral
loads in the lungs. This study, therefore, provides no
insight into either the prevalence or relevance of pul-
monary CMV reactivations. Of note, previous studies
have shown that pulmonary reactivation may occur
without the concurrent viremia [4, 38, 39]. Furthermore,
we focused exclusively on the occurrence of reactivation
while patients were on mechanical ventilation (primary
analysis) or in the ICU (sensitivity analysis), as we con-
sidered these to be the most relevant time windows to
potentially treat or prevent CMV reactivation in the ICU.
However, because of this deliberate focus we cannot
provide information about possible episodes of reactiva-
tion that may have occurred later. Likewise we did not
investigate the occurrence of reactivations after day 35 in
the ICU. Thus, this study only provides insight into the
short-term effects of systemic CMV reactivation in ARDS
patients in settings in which screening or antiviral pro-
phylaxis is not part of routine clinical practice.
In conclusion, systemic reactivation of CMV in
immunocompetent ARDS patients is common and inde-
pendently associated with death in the ICU. These
findings support the need for future studies to better
predict CMV reactivation as well as to evaluate the effi-
cacy of treatment strategies directed against CMV
reactivation in these patients.
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